Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group
•Allogeneic hematopoietic stem cell transplantation is beneficial for patients with mature T cell and natural killer cell neoplasms.•Cord blood transplantation (CBT) resulted in favorable outcomes with a lower risk of relapse.•CBT could be a preferred option, especially for patients with uncontrolle...
Gespeichert in:
| Veröffentlicht in: | Biology of blood and marrow transplantation 2020-12, Vol.26 (12), p.2346-2358 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2358 |
|---|---|
| container_issue | 12 |
| container_start_page | 2346 |
| container_title | Biology of blood and marrow transplantation |
| container_volume | 26 |
| creator | Watanabe, Mizuki Kanda, Junya Arai, Yasuyuki Hishizawa, Masakatsu Nishikori, Momoko Ishikawa, Takayuki Imada, Kazunori Ueda, Yasunori Akasaka, Takashi Yonezawa, Akihito Nohgawa, Masaharu Kitano, Toshiyuki Itoh, Mitsuru Takeoka, Tomoharu Moriguchi, Toshinori Yago, Kazuhiro Arima, Nobuyoshi Anzai, Naoyuki Watanabe, Mitsumasa Kondo, Tadakazu Takaori-Kondo, Akifumi |
| description | •Allogeneic hematopoietic stem cell transplantation is beneficial for patients with mature T cell and natural killer cell neoplasms.•Cord blood transplantation (CBT) resulted in favorable outcomes with a lower risk of relapse.•CBT could be a preferred option, especially for patients with uncontrolled diseases.•Better control of lymphoma at transplantation is a key to improved outcomes.
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the key strategy to cure patients with mature T and natural killer (NK) cell lymphomas/leukemia, especially those with relapsed/refractory diseases, there is no consensus strategy for donor selection. We retrospectively analyzed the outcomes of allo-HSCT in 111 patients in 15 Japanese institutions as a multi-institutional joint research project. Thirty-nine patients received bone marrow or peripheral blood stem cell transplantation from related donors (rBMT/rPBSCT), 37 received BMT/PBSCT from unrelated donors (uBMT/uPBSCT), and 35 received cord blood transplantation (CBT). Overall survival (OS) and progression-free survival (PFS) at 4 years were 42% and 34%, respectively. The cumulative incidences of relapse and nonrelapse mortality were 43% and 25%. In multivariate analysis, CBT showed comparable OS with rBMT/rPBSCT (rBMT/rPBSCT versus CBT: hazard ratio [HR], 1.63; P = .264) and better OS compared with uBMT/uPBSCT (HR, 2.99; P = .010), with a trend toward a lower relapse rate (rBMT/rPBSCT versus CBT: HR, 2.60; P = .010; uBMT/uPBSCT versus CBT: HR, 2.05; P = .082). This superiority of CBT was more definite in on-disease patients (OS: rBMT/rPBSCT versus CBT: HR, 5.52; P = .021; uBMT/uPBSCT versus CBT: HR, 6.80; P = .007). Better disease control was also strongly associated with better OS and PFS with lower relapse rate. In conclusion, allo-HSCT is beneficial for the survival of patients with mature T and NK cell lymphomas/leukemia if performed in a timely fashion. Since CBT showed favorable survival with a lower relapse risk, it could be a preferred alternative, especially in on-disease patients. |
| doi_str_mv | 10.1016/j.bbmt.2020.07.032 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2429780468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S108387912030464X</els_id><sourcerecordid>2429780468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-cf04f575d5a36f9c2cd104dbef0684bb08d2744c5de8eb555bf4644096a638143</originalsourceid><addsrcrecordid>eNqNkc1u1TAQRiMEoqXwAiyQl0gowfFP4khsqgBt1VIWvawtxxmDrxI72A6oD8U74qtcuqxYeTw6Z2TPVxSva1zVuG7e76thmFNFMMEVbitMyZPitOaElg2nzdNcY0FL0Xb1SfEixj3GuGWie16cUNJSwTE-Lf5czYvSCXmDPnrnA7rza9CAvEPn0-S_gwOr0SXMKvnFW0j5dpdgRj1ME9oF5eIyKZdUslkxecAXldYAaLcRyo3o9tBRE7q20wRh69-Cz16cI7IOpR-Aru998o-Mvgh-XV4Wz4yaIrw6nmfFt8-fdv1lefP14qo_vyk15U0qtcHM8JaPXNHGdJroscZsHMDgRrBhwGIkLWOajyBg4JwPhjWM4a5RDRU1o2fF223uEvzPFWKSs406P0s58GuUhJGuFZg1IqNkQ3XwMQYwcgl2VuFe1lgeYpJ7eYhJHmKSuJU5piy9Oc5fhxnGB-VfLhl4twG_YfAmagtOwwOWg-Qd44yQXFGeafH_dG-3jfZ-dSmrHzYV8jp_WQjyqI82gE5y9Paxj_wFx-TGnw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429780468</pqid></control><display><type>article</type><title>Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Access via ScienceDirect (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Watanabe, Mizuki ; Kanda, Junya ; Arai, Yasuyuki ; Hishizawa, Masakatsu ; Nishikori, Momoko ; Ishikawa, Takayuki ; Imada, Kazunori ; Ueda, Yasunori ; Akasaka, Takashi ; Yonezawa, Akihito ; Nohgawa, Masaharu ; Kitano, Toshiyuki ; Itoh, Mitsuru ; Takeoka, Tomoharu ; Moriguchi, Toshinori ; Yago, Kazuhiro ; Arima, Nobuyoshi ; Anzai, Naoyuki ; Watanabe, Mitsumasa ; Kondo, Tadakazu ; Takaori-Kondo, Akifumi</creator><creatorcontrib>Watanabe, Mizuki ; Kanda, Junya ; Arai, Yasuyuki ; Hishizawa, Masakatsu ; Nishikori, Momoko ; Ishikawa, Takayuki ; Imada, Kazunori ; Ueda, Yasunori ; Akasaka, Takashi ; Yonezawa, Akihito ; Nohgawa, Masaharu ; Kitano, Toshiyuki ; Itoh, Mitsuru ; Takeoka, Tomoharu ; Moriguchi, Toshinori ; Yago, Kazuhiro ; Arima, Nobuyoshi ; Anzai, Naoyuki ; Watanabe, Mitsumasa ; Kondo, Tadakazu ; Takaori-Kondo, Akifumi ; Kyoto Stem Cell Transplantation Group (KSCTG) ; Kyoto Stem Cell Transplantat Grp K</creatorcontrib><description>•Allogeneic hematopoietic stem cell transplantation is beneficial for patients with mature T cell and natural killer cell neoplasms.•Cord blood transplantation (CBT) resulted in favorable outcomes with a lower risk of relapse.•CBT could be a preferred option, especially for patients with uncontrolled diseases.•Better control of lymphoma at transplantation is a key to improved outcomes.
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the key strategy to cure patients with mature T and natural killer (NK) cell lymphomas/leukemia, especially those with relapsed/refractory diseases, there is no consensus strategy for donor selection. We retrospectively analyzed the outcomes of allo-HSCT in 111 patients in 15 Japanese institutions as a multi-institutional joint research project. Thirty-nine patients received bone marrow or peripheral blood stem cell transplantation from related donors (rBMT/rPBSCT), 37 received BMT/PBSCT from unrelated donors (uBMT/uPBSCT), and 35 received cord blood transplantation (CBT). Overall survival (OS) and progression-free survival (PFS) at 4 years were 42% and 34%, respectively. The cumulative incidences of relapse and nonrelapse mortality were 43% and 25%. In multivariate analysis, CBT showed comparable OS with rBMT/rPBSCT (rBMT/rPBSCT versus CBT: hazard ratio [HR], 1.63; P = .264) and better OS compared with uBMT/uPBSCT (HR, 2.99; P = .010), with a trend toward a lower relapse rate (rBMT/rPBSCT versus CBT: HR, 2.60; P = .010; uBMT/uPBSCT versus CBT: HR, 2.05; P = .082). This superiority of CBT was more definite in on-disease patients (OS: rBMT/rPBSCT versus CBT: HR, 5.52; P = .021; uBMT/uPBSCT versus CBT: HR, 6.80; P = .007). Better disease control was also strongly associated with better OS and PFS with lower relapse rate. In conclusion, allo-HSCT is beneficial for the survival of patients with mature T and NK cell lymphomas/leukemia if performed in a timely fashion. Since CBT showed favorable survival with a lower relapse risk, it could be a preferred alternative, especially in on-disease patients.</description><identifier>ISSN: 1083-8791</identifier><identifier>EISSN: 1523-6536</identifier><identifier>DOI: 10.1016/j.bbmt.2020.07.032</identifier><identifier>PMID: 32738500</identifier><language>eng</language><publisher>NEW YORK: Elsevier Inc</publisher><subject>Allogenic hematopoietic stem cell transplantation ; Bone Marrow Transplantation ; Cord Blood Stem Cell Transplantation ; Cord blood transplantation ; Donor source ; Graft vs Host Disease ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunology ; Killer Cells, Natural ; Life Sciences & Biomedicine ; Mature T and NK cell neoplasms ; Neoplasms ; NK cell lymphomas/leukemia ; Retrospective Studies ; Science & Technology ; T cell lymphomas ; T-Lymphocytes ; Transplantation</subject><ispartof>Biology of blood and marrow transplantation, 2020-12, Vol.26 (12), p.2346-2358</ispartof><rights>2020 American Society for Transplantation and Cellular Therapy</rights><rights>Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000594542200035</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c356t-cf04f575d5a36f9c2cd104dbef0684bb08d2744c5de8eb555bf4644096a638143</citedby><cites>FETCH-LOGICAL-c356t-cf04f575d5a36f9c2cd104dbef0684bb08d2744c5de8eb555bf4644096a638143</cites><orcidid>0000-0002-4030-4653 ; 0000-0002-6704-3633</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbmt.2020.07.032$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,28257,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32738500$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watanabe, Mizuki</creatorcontrib><creatorcontrib>Kanda, Junya</creatorcontrib><creatorcontrib>Arai, Yasuyuki</creatorcontrib><creatorcontrib>Hishizawa, Masakatsu</creatorcontrib><creatorcontrib>Nishikori, Momoko</creatorcontrib><creatorcontrib>Ishikawa, Takayuki</creatorcontrib><creatorcontrib>Imada, Kazunori</creatorcontrib><creatorcontrib>Ueda, Yasunori</creatorcontrib><creatorcontrib>Akasaka, Takashi</creatorcontrib><creatorcontrib>Yonezawa, Akihito</creatorcontrib><creatorcontrib>Nohgawa, Masaharu</creatorcontrib><creatorcontrib>Kitano, Toshiyuki</creatorcontrib><creatorcontrib>Itoh, Mitsuru</creatorcontrib><creatorcontrib>Takeoka, Tomoharu</creatorcontrib><creatorcontrib>Moriguchi, Toshinori</creatorcontrib><creatorcontrib>Yago, Kazuhiro</creatorcontrib><creatorcontrib>Arima, Nobuyoshi</creatorcontrib><creatorcontrib>Anzai, Naoyuki</creatorcontrib><creatorcontrib>Watanabe, Mitsumasa</creatorcontrib><creatorcontrib>Kondo, Tadakazu</creatorcontrib><creatorcontrib>Takaori-Kondo, Akifumi</creatorcontrib><creatorcontrib>Kyoto Stem Cell Transplantation Group (KSCTG)</creatorcontrib><creatorcontrib>Kyoto Stem Cell Transplantat Grp K</creatorcontrib><title>Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group</title><title>Biology of blood and marrow transplantation</title><addtitle>BIOL BLOOD MARROW TR</addtitle><addtitle>Biol Blood Marrow Transplant</addtitle><description>•Allogeneic hematopoietic stem cell transplantation is beneficial for patients with mature T cell and natural killer cell neoplasms.•Cord blood transplantation (CBT) resulted in favorable outcomes with a lower risk of relapse.•CBT could be a preferred option, especially for patients with uncontrolled diseases.•Better control of lymphoma at transplantation is a key to improved outcomes.
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the key strategy to cure patients with mature T and natural killer (NK) cell lymphomas/leukemia, especially those with relapsed/refractory diseases, there is no consensus strategy for donor selection. We retrospectively analyzed the outcomes of allo-HSCT in 111 patients in 15 Japanese institutions as a multi-institutional joint research project. Thirty-nine patients received bone marrow or peripheral blood stem cell transplantation from related donors (rBMT/rPBSCT), 37 received BMT/PBSCT from unrelated donors (uBMT/uPBSCT), and 35 received cord blood transplantation (CBT). Overall survival (OS) and progression-free survival (PFS) at 4 years were 42% and 34%, respectively. The cumulative incidences of relapse and nonrelapse mortality were 43% and 25%. In multivariate analysis, CBT showed comparable OS with rBMT/rPBSCT (rBMT/rPBSCT versus CBT: hazard ratio [HR], 1.63; P = .264) and better OS compared with uBMT/uPBSCT (HR, 2.99; P = .010), with a trend toward a lower relapse rate (rBMT/rPBSCT versus CBT: HR, 2.60; P = .010; uBMT/uPBSCT versus CBT: HR, 2.05; P = .082). This superiority of CBT was more definite in on-disease patients (OS: rBMT/rPBSCT versus CBT: HR, 5.52; P = .021; uBMT/uPBSCT versus CBT: HR, 6.80; P = .007). Better disease control was also strongly associated with better OS and PFS with lower relapse rate. In conclusion, allo-HSCT is beneficial for the survival of patients with mature T and NK cell lymphomas/leukemia if performed in a timely fashion. Since CBT showed favorable survival with a lower relapse risk, it could be a preferred alternative, especially in on-disease patients.</description><subject>Allogenic hematopoietic stem cell transplantation</subject><subject>Bone Marrow Transplantation</subject><subject>Cord Blood Stem Cell Transplantation</subject><subject>Cord blood transplantation</subject><subject>Donor source</subject><subject>Graft vs Host Disease</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Immunology</subject><subject>Killer Cells, Natural</subject><subject>Life Sciences & Biomedicine</subject><subject>Mature T and NK cell neoplasms</subject><subject>Neoplasms</subject><subject>NK cell lymphomas/leukemia</subject><subject>Retrospective Studies</subject><subject>Science & Technology</subject><subject>T cell lymphomas</subject><subject>T-Lymphocytes</subject><subject>Transplantation</subject><issn>1083-8791</issn><issn>1523-6536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkc1u1TAQRiMEoqXwAiyQl0gowfFP4khsqgBt1VIWvawtxxmDrxI72A6oD8U74qtcuqxYeTw6Z2TPVxSva1zVuG7e76thmFNFMMEVbitMyZPitOaElg2nzdNcY0FL0Xb1SfEixj3GuGWie16cUNJSwTE-Lf5czYvSCXmDPnrnA7rza9CAvEPn0-S_gwOr0SXMKvnFW0j5dpdgRj1ME9oF5eIyKZdUslkxecAXldYAaLcRyo3o9tBRE7q20wRh69-Cz16cI7IOpR-Aru998o-Mvgh-XV4Wz4yaIrw6nmfFt8-fdv1lefP14qo_vyk15U0qtcHM8JaPXNHGdJroscZsHMDgRrBhwGIkLWOajyBg4JwPhjWM4a5RDRU1o2fF223uEvzPFWKSs406P0s58GuUhJGuFZg1IqNkQ3XwMQYwcgl2VuFe1lgeYpJ7eYhJHmKSuJU5piy9Oc5fhxnGB-VfLhl4twG_YfAmagtOwwOWg-Qd44yQXFGeafH_dG-3jfZ-dSmrHzYV8jp_WQjyqI82gE5y9Paxj_wFx-TGnw</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Watanabe, Mizuki</creator><creator>Kanda, Junya</creator><creator>Arai, Yasuyuki</creator><creator>Hishizawa, Masakatsu</creator><creator>Nishikori, Momoko</creator><creator>Ishikawa, Takayuki</creator><creator>Imada, Kazunori</creator><creator>Ueda, Yasunori</creator><creator>Akasaka, Takashi</creator><creator>Yonezawa, Akihito</creator><creator>Nohgawa, Masaharu</creator><creator>Kitano, Toshiyuki</creator><creator>Itoh, Mitsuru</creator><creator>Takeoka, Tomoharu</creator><creator>Moriguchi, Toshinori</creator><creator>Yago, Kazuhiro</creator><creator>Arima, Nobuyoshi</creator><creator>Anzai, Naoyuki</creator><creator>Watanabe, Mitsumasa</creator><creator>Kondo, Tadakazu</creator><creator>Takaori-Kondo, Akifumi</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4030-4653</orcidid><orcidid>https://orcid.org/0000-0002-6704-3633</orcidid></search><sort><creationdate>202012</creationdate><title>Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group</title><author>Watanabe, Mizuki ; Kanda, Junya ; Arai, Yasuyuki ; Hishizawa, Masakatsu ; Nishikori, Momoko ; Ishikawa, Takayuki ; Imada, Kazunori ; Ueda, Yasunori ; Akasaka, Takashi ; Yonezawa, Akihito ; Nohgawa, Masaharu ; Kitano, Toshiyuki ; Itoh, Mitsuru ; Takeoka, Tomoharu ; Moriguchi, Toshinori ; Yago, Kazuhiro ; Arima, Nobuyoshi ; Anzai, Naoyuki ; Watanabe, Mitsumasa ; Kondo, Tadakazu ; Takaori-Kondo, Akifumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-cf04f575d5a36f9c2cd104dbef0684bb08d2744c5de8eb555bf4644096a638143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allogenic hematopoietic stem cell transplantation</topic><topic>Bone Marrow Transplantation</topic><topic>Cord Blood Stem Cell Transplantation</topic><topic>Cord blood transplantation</topic><topic>Donor source</topic><topic>Graft vs Host Disease</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Immunology</topic><topic>Killer Cells, Natural</topic><topic>Life Sciences & Biomedicine</topic><topic>Mature T and NK cell neoplasms</topic><topic>Neoplasms</topic><topic>NK cell lymphomas/leukemia</topic><topic>Retrospective Studies</topic><topic>Science & Technology</topic><topic>T cell lymphomas</topic><topic>T-Lymphocytes</topic><topic>Transplantation</topic><toplevel>online_resources</toplevel><creatorcontrib>Watanabe, Mizuki</creatorcontrib><creatorcontrib>Kanda, Junya</creatorcontrib><creatorcontrib>Arai, Yasuyuki</creatorcontrib><creatorcontrib>Hishizawa, Masakatsu</creatorcontrib><creatorcontrib>Nishikori, Momoko</creatorcontrib><creatorcontrib>Ishikawa, Takayuki</creatorcontrib><creatorcontrib>Imada, Kazunori</creatorcontrib><creatorcontrib>Ueda, Yasunori</creatorcontrib><creatorcontrib>Akasaka, Takashi</creatorcontrib><creatorcontrib>Yonezawa, Akihito</creatorcontrib><creatorcontrib>Nohgawa, Masaharu</creatorcontrib><creatorcontrib>Kitano, Toshiyuki</creatorcontrib><creatorcontrib>Itoh, Mitsuru</creatorcontrib><creatorcontrib>Takeoka, Tomoharu</creatorcontrib><creatorcontrib>Moriguchi, Toshinori</creatorcontrib><creatorcontrib>Yago, Kazuhiro</creatorcontrib><creatorcontrib>Arima, Nobuyoshi</creatorcontrib><creatorcontrib>Anzai, Naoyuki</creatorcontrib><creatorcontrib>Watanabe, Mitsumasa</creatorcontrib><creatorcontrib>Kondo, Tadakazu</creatorcontrib><creatorcontrib>Takaori-Kondo, Akifumi</creatorcontrib><creatorcontrib>Kyoto Stem Cell Transplantation Group (KSCTG)</creatorcontrib><creatorcontrib>Kyoto Stem Cell Transplantat Grp K</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biology of blood and marrow transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watanabe, Mizuki</au><au>Kanda, Junya</au><au>Arai, Yasuyuki</au><au>Hishizawa, Masakatsu</au><au>Nishikori, Momoko</au><au>Ishikawa, Takayuki</au><au>Imada, Kazunori</au><au>Ueda, Yasunori</au><au>Akasaka, Takashi</au><au>Yonezawa, Akihito</au><au>Nohgawa, Masaharu</au><au>Kitano, Toshiyuki</au><au>Itoh, Mitsuru</au><au>Takeoka, Tomoharu</au><au>Moriguchi, Toshinori</au><au>Yago, Kazuhiro</au><au>Arima, Nobuyoshi</au><au>Anzai, Naoyuki</au><au>Watanabe, Mitsumasa</au><au>Kondo, Tadakazu</au><au>Takaori-Kondo, Akifumi</au><aucorp>Kyoto Stem Cell Transplantation Group (KSCTG)</aucorp><aucorp>Kyoto Stem Cell Transplantat Grp K</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group</atitle><jtitle>Biology of blood and marrow transplantation</jtitle><stitle>BIOL BLOOD MARROW TR</stitle><addtitle>Biol Blood Marrow Transplant</addtitle><date>2020-12</date><risdate>2020</risdate><volume>26</volume><issue>12</issue><spage>2346</spage><epage>2358</epage><pages>2346-2358</pages><issn>1083-8791</issn><eissn>1523-6536</eissn><abstract>•Allogeneic hematopoietic stem cell transplantation is beneficial for patients with mature T cell and natural killer cell neoplasms.•Cord blood transplantation (CBT) resulted in favorable outcomes with a lower risk of relapse.•CBT could be a preferred option, especially for patients with uncontrolled diseases.•Better control of lymphoma at transplantation is a key to improved outcomes.
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the key strategy to cure patients with mature T and natural killer (NK) cell lymphomas/leukemia, especially those with relapsed/refractory diseases, there is no consensus strategy for donor selection. We retrospectively analyzed the outcomes of allo-HSCT in 111 patients in 15 Japanese institutions as a multi-institutional joint research project. Thirty-nine patients received bone marrow or peripheral blood stem cell transplantation from related donors (rBMT/rPBSCT), 37 received BMT/PBSCT from unrelated donors (uBMT/uPBSCT), and 35 received cord blood transplantation (CBT). Overall survival (OS) and progression-free survival (PFS) at 4 years were 42% and 34%, respectively. The cumulative incidences of relapse and nonrelapse mortality were 43% and 25%. In multivariate analysis, CBT showed comparable OS with rBMT/rPBSCT (rBMT/rPBSCT versus CBT: hazard ratio [HR], 1.63; P = .264) and better OS compared with uBMT/uPBSCT (HR, 2.99; P = .010), with a trend toward a lower relapse rate (rBMT/rPBSCT versus CBT: HR, 2.60; P = .010; uBMT/uPBSCT versus CBT: HR, 2.05; P = .082). This superiority of CBT was more definite in on-disease patients (OS: rBMT/rPBSCT versus CBT: HR, 5.52; P = .021; uBMT/uPBSCT versus CBT: HR, 6.80; P = .007). Better disease control was also strongly associated with better OS and PFS with lower relapse rate. In conclusion, allo-HSCT is beneficial for the survival of patients with mature T and NK cell lymphomas/leukemia if performed in a timely fashion. Since CBT showed favorable survival with a lower relapse risk, it could be a preferred alternative, especially in on-disease patients.</abstract><cop>NEW YORK</cop><pub>Elsevier Inc</pub><pmid>32738500</pmid><doi>10.1016/j.bbmt.2020.07.032</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-4030-4653</orcidid><orcidid>https://orcid.org/0000-0002-6704-3633</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-8791 |
| ispartof | Biology of blood and marrow transplantation, 2020-12, Vol.26 (12), p.2346-2358 |
| issn | 1083-8791 1523-6536 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2429780468 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via ScienceDirect (Elsevier); Alma/SFX Local Collection |
| subjects | Allogenic hematopoietic stem cell transplantation Bone Marrow Transplantation Cord Blood Stem Cell Transplantation Cord blood transplantation Donor source Graft vs Host Disease Hematology Hematopoietic Stem Cell Transplantation Humans Immunology Killer Cells, Natural Life Sciences & Biomedicine Mature T and NK cell neoplasms Neoplasms NK cell lymphomas/leukemia Retrospective Studies Science & Technology T cell lymphomas T-Lymphocytes Transplantation |
| title | Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T21%3A49%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Donor%20Source%20on%20Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplantation%20for%20Mature%20T%20Cell%20and%20Natural%20Killer%20Cell%20Neoplasms%20in%20the%20Kyoto%20Stem%20Cell%20Transplantation%20Group&rft.jtitle=Biology%20of%20blood%20and%20marrow%20transplantation&rft.au=Watanabe,%20Mizuki&rft.aucorp=Kyoto%20Stem%20Cell%20Transplantation%20Group%20(KSCTG)&rft.date=2020-12&rft.volume=26&rft.issue=12&rft.spage=2346&rft.epage=2358&rft.pages=2346-2358&rft.issn=1083-8791&rft.eissn=1523-6536&rft_id=info:doi/10.1016/j.bbmt.2020.07.032&rft_dat=%3Cproquest_cross%3E2429780468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2429780468&rft_id=info:pmid/32738500&rft_els_id=S108387912030464X&rfr_iscdi=true |